Abstract |
Etravirine (Intelence®), an oral next-generation non- nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor HIV-1 strains resistant to other antiretroviral agents has recently been expanded to include pediatric patients aged ≥ 6 to <18 years. At 24 and 48 weeks in an open-label trial, etravirine 5.2 mg/kg twice daily (maximum dosage 200 mg twice daily) plus an optimized background therapy regimen achieved complete viral response (defined as HIV-1 RNA <50 copies/mL) in approximately half of treatment-experienced children and adolescents with HIV-1 infection and evidence of viral replication, and had an acceptable tolerability profile.
|
Authors | Katherine A Lyseng-Williamson |
Journal | Paediatric drugs
(Paediatr Drugs)
Vol. 14
Issue 5
Pg. 345-50
(Oct 01 2012)
ISSN: 1179-2019 [Electronic] Switzerland |
PMID | 22897163
(Publication Type: Journal Article)
|
Chemical References |
- Anti-HIV Agents
- Nitriles
- Pyridazines
- Pyrimidines
- Reverse Transcriptase Inhibitors
- etravirine
|
Topics |
- Adolescent
- Anti-HIV Agents
(administration & dosage, pharmacology, therapeutic use)
- Child
- Drug Therapy, Combination
- HIV Infections
(drug therapy, virology)
- HIV-1
(drug effects, genetics)
- Humans
- Nitriles
- Pyridazines
(administration & dosage, adverse effects, therapeutic use)
- Pyrimidines
- Reverse Transcriptase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
|